Published in Biochem Pharmacol on September 01, 1987
Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol (2005) 1.11
Ginkgolide B reduces atherogenesis and vascular inflammation in ApoE(-/-) mice. PLoS One (2012) 0.82
Hepatic fibrosis in biliary-obstructed rats is prevented by Ginkgo biloba treatment. World J Gastroenterol (2005) 0.80
Ginkgolide B increases hydrogen sulfide and protects against endothelial dysfunction in diabetic rats. Croat Med J (2015) 0.78
The leaf extract of Ginkgo Biloba L. suppresses oxidized LDL-stimulated fibronectin production through an antioxidant action in rat mesangial cells. Br J Pharmacol (2004) 0.75
Perspectives in platelet-activating factor research. Pharmacol Rev (1987) 5.27
A role for phosphoinositide 3-kinase in bacterial invasion. Science (1996) 2.46
Secretory phospholipase A2 generates the novel lipid mediator lysophosphatidic acid in membrane microvesicles shed from activated cells. Cell (1995) 1.99
Prognostic value of admission plasma glucose and HbA in acute myocardial infarction. Diabet Med (2004) 1.93
Loss of endothelium-dependent relaxant activity in the pulmonary circulation of rats exposed to chronic hypoxia. J Clin Invest (1991) 1.91
Atrial natriuretic peptide concentrations and pulmonary hemodynamics in patients with pulmonary artery hypertension. Am Rev Respir Dis (1987) 1.87
Relationship between flavonoid structure and inhibition of phosphatidylinositol 3-kinase: a comparison with tyrosine kinase and protein kinase C inhibition. Biochem Pharmacol (1997) 1.64
Integrin-dependent translocation of phosphoinositide 3-kinase to the cytoskeleton of thrombin-activated platelets involves specific interactions of p85 alpha with actin filaments and focal adhesion kinase. J Cell Biol (1995) 1.57
A critical role for phosphoinositide 3-kinase upstream of Gab1 and SHP2 in the activation of ras and mitogen-activated protein kinases by epidermal growth factor. J Biol Chem (2000) 1.56
Phosphatidic and lysophosphatidic acid production in phospholipase C-and thrombin-treated platelets. Possible involvement of a platelet lipase. Biochimie (1978) 1.56
A genetic defect in phosphatidylcholine biosynthesis triggers apoptosis in Chinese hamster ovary cells. J Biol Chem (1996) 1.52
The role of neutrophils and platelet-activating factor in mediating experimental pancreatitis. Gastroenterology (1996) 1.49
Human endothelial cells are target for platelet-activating factor. I. Platelet-activating factor induces changes in cytoskeleton structures. J Immunol (1987) 1.46
Role of free radicals and platelet-activating factor in the genesis of intestinal motor disturbances induced by Escherichia coli endotoxins in rats. Gastroenterology (1991) 1.43
An investigation into the possible involvement of platelet activating factor in experimental allergic encephalomyelitis in rats. Agents Actions (1989) 1.42
Regulation of IgE production from human mononuclear cells by beta 2-adrenoceptor agonists. Clin Exp Allergy (1995) 1.42
Interaction of pp60c-src, phospholipase C, inositol-lipid, and diacyglycerol kinases with the cytoskeletons of thrombin-stimulated platelets. J Biol Chem (1991) 1.37
Interleukin-9 potentiates the interleukin-4-induced immunoglobulin (IgG, IgM and IgE) production by normal human B lymphocytes. Eur J Immunol (1993) 1.35
Interleukin-9 potentiates the interleukin-4-induced IgE and IgG1 release from murine B lymphocytes. Immunology (1993) 1.35
Comparative effects of indomethacin, acetylenic acids, 15-HETE, nordihydroguaiaretic acid and BW755C on the metabolism of arachidonic acid in human leukocytes and platelets. Prostaglandins Leukot Med (1984) 1.30
Lysophosphatidic acid-induced Ca2+ mobilization in human A431 cells: structure-activity analysis. Biochem J (1995) 1.26
Platelet activating factor (PAF). A review of its effects, antagonists and possible future clinical implications (Part I). Drugs (1991) 1.25
Lysophosphatidic acid as a phospholipid mediator: pathways of synthesis. FEBS Lett (1997) 1.25
Endothelin and Ca++ agonist Bay K 8644: different vasoconstrictive properties. Biochem Biophys Res Commun (1988) 1.20
Atrial natriuretic factor in chronic obstructive lung disease with pulmonary hypertension. Physiological correlates and response to peptide infusion. J Clin Invest (1989) 1.19
Specific inhibition of PAF-acether-induced platelet activation by BN 52021 and comparison with the PAF-acether inhibitors kadsurenone and CV 3988. Eur J Pharmacol (1986) 1.17
Ischemia and reperfusion-induced histologic changes in the rat retina. Demonstration of a free radical-mediated mechanism. Invest Ophthalmol Vis Sci (1991) 1.17
Decreased leukotriene B4 synthesis in smokers' alveolar macrophages in vitro. J Clin Invest (1986) 1.17
Sphingomyelinases and Niemann-Pick disease. J Clin Chem Clin Biochem (1986) 1.16
Biosynthetic labelling of platelet activating factor from radioactive acetate by stimulated platelets. Nature (1981) 1.15
Lipid products of phosphoinositide 3-kinase interact with Rac1 GTPase and stimulate GDP dissociation. J Biol Chem (1998) 1.15
Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res (2002) 1.12
Flavonoids and the inhibition of PKC and PI 3-kinase. Gen Pharmacol (1999) 1.12
Na+ and K+ transport damage induced by oxygen free radicals in human red cell membranes. J Biol Chem (1983) 1.11
Studies on ether phospholipids. II. Comparative composition of various tissues from human, rat and guinea pig. Biochim Biophys Acta (1984) 1.11
The effect of the selective PAF antagonist BN 52021 on PAF- and antigen-induced bronchial hyper-reactivity and eosinophil accumulation. Eur J Pharmacol (1988) 1.11
Distinct platelet-activating factor binding sites in synaptic endings and in intracellular membranes of rat cerebral cortex. J Biol Chem (1990) 1.10
Phosphatidylinositol 3,4,5-trisphosphate-dependent stimulation of phospholipase C-gamma2 is an early key event in FcgammaRIIA-mediated activation of human platelets. J Biol Chem (1998) 1.10
Pharmacological modulation of the bronchopulmonary action of the vasoactive peptide, endothelin, administered by aerosol in the guinea-pig. Biochem Biophys Res Commun (1989) 1.10
Atrial natriuretic factor attenuates the pulmonary pressor response to hypoxia. J Appl Physiol (1985) (1988) 1.09
Hepatic lipase induces the formation of pre-beta 1 high density lipoprotein (HDL) from triacylglycerol-rich HDL2. A study comparing liver perfusion to in vitro incubation with lipases. J Biol Chem (1994) 1.09
Platelet membrane phospholipid asymmetry: from the characterization of a scramblase activity to the identification of an essential protein mutated in Scott syndrome. J Thromb Haemost (2011) 1.08
Effects of lysophosphatidic acid on proliferation and cytosolic Ca++ of human adult vascular smooth muscle cells in culture. Thromb Res (1999) 1.07
Eosinophil-rich human polymorphonuclear leukocyte preparations characteristically release leukotriene C4 on ionophore A23187 challenge. J Allergy Clin Immunol (1984) 1.06
Involvement of platelet glycoprotein IIb-IIIa (alpha IIb-beta 3 integrin) in thrombin-induced synthesis of phosphatidylinositol 3',4'-bisphosphate. J Biol Chem (1991) 1.06
Relationship between phosphoinositide kinase activities and protein tyrosine phosphorylation in plasma membranes from A431 cells. Biochem J (1990) 1.06
Human platelet aggregation induced by 1-alkyl-lysophosphatidic acid and its analogs: a new group of phospholipid mediators? Biochem Biophys Res Commun (1982) 1.05
An epidermal growth factor receptor/Gab1 signaling pathway is required for activation of phosphoinositide 3-kinase by lysophosphatidic acid. J Biol Chem (1999) 1.05
Production of phosphatidylinositol 3,4,5-trisphosphate and phosphatidic acid in platelet rafts: evidence for a critical role of cholesterol-enriched domains in human platelet activation. Biochemistry (2001) 1.05
Characterization and properties of a phosphatidylinositol phosphodiesterase (phospholipase C) from platelet cytosol. FEBS Lett (1979) 1.04
Atrial natriuretic factor (ANF) is a potent bronchodilator in asthma. J Allergy Clin Immunol (1990) 1.03
Induction of nitric oxide synthase by lipoteichoic acid from Staphylococcus aureus in vascular smooth muscle cells. FEBS Lett (1992) 1.03
Phosphatidylinositol 3-kinase inhibitors block aortic smooth muscle cell proliferation in mid-late G1 phase: effect on cyclin-dependent kinase 2 and the inhibitory protein p27KIP1. Biochem Biophys Res Commun (1998) 1.03
Interference of BN 52021 (ginkgolide B) with the bronchopulmonary effects of PAF-acether in the guinea-pig. Eur J Pharmacol (1986) 1.02
Platelets mediate the action of diethylcarbamazine on microfilariae. Nature (1987) 1.02
Involvement of platelet activating factor in respiratory anaphylaxis, demonstrated by PAF-acether inhibitor BN 52021. Lancet (1985) 1.01
Effect of long-term treatment with platelet-activating factor on IL-1 and IL-2 production by rat spleen cells. J Immunol (1990) 1.01
Tyrosine phosphorylation and relocation of SHIP are integrin-mediated in thrombin-stimulated human blood platelets. J Biol Chem (1997) 1.00
Characterization of effect of N-formyl-methionyl-leucyl-phenylalanine on leukotriene synthesis in human polymorphonuclear leukocytes. Inflammation (1985) 1.00
Non-enzymatic degradation of acid-soluble calf skin collagen by superoxide ion: protective effect of flavonoids. Biochem Pharmacol (1983) 1.00
The novel inositol lipid phosphatidylinositol 3,4-bisphosphate is produced by human blood platelets upon thrombin stimulation. Biochem J (1990) 1.00
An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients. AIDS (2001) 0.99
Stimulation of K+ fluxes by diuretic drugs in human red cells. Biochem Pharmacol (1984) 0.99
Vascular mechanism of action of endothelin-1: effect of Ca2+ antagonists. J Cardiovasc Pharmacol (1989) 0.99
Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids (1997) 0.99
Biochemical characterization of plasma membranes and intracellular membranes isolated from human platelets using Percoll gradients. Biochim Biophys Acta (1986) 0.99
Inhibition of PAF-acether induced weal and flare reaction in man by a specific PAF antagonist. Prostaglandins (1986) 0.98
Ultraviolet-treated lipoproteins as a model system for the study of the biological effects of lipid peroxides on cultured cells. II. Uptake and cytotoxicity of ultraviolet-treated LDL on lymphoid cell lines. Biochim Biophys Acta (1990) 0.98
Cytidylyltransferase translocation onto endoplasmic reticulum and increased de novo synthesis without phosphatidylcholine accumulation in Krebs-II ascite cells. Biochim Biophys Acta (1991) 0.97
Serum triglycerides are a predictive factor for the development and the progression of renal and retinal complications in patients with type 1 diabetes. Diabetes Metab (2004) 0.97
Superoxide dismutase (SOD) and the PAF-antagonist (BN 52021) reduce small intestinal damage induced by ischemia-reperfusion. Free Radic Res Commun (1991) 0.97
PAF. A review of its effects, antagonists and possible future clinical implications (Part II). Drugs (1991) 0.97
Isolation and characterization of plasma membranes from krebs II ascite cells using Percoll gradient. Biochim Biophys Acta (1982) 0.97
The integrin alpha IIb/beta 3 in human platelet signal transduction. Biochem Pharmacol (2000) 0.97
Platelet activating factor (PAF-acether) promotes an early degradation of phosphatidylinositol-4,5-biphosphate in rabbit platelets. FEBS Lett (1983) 0.97
Differential activation by fMet-Leu-Phe and phorbol ester of a plasma membrane phosphatidylcholine-specific phospholipase D in human neutrophil. FEBS Lett (1989) 0.96
Anti-thrombin therapy during warm ischemia and cold preservation prevents chronic kidney graft fibrosis in a DCD model. Am J Transplant (2009) 0.96
Phosphatidylcholine cycle and regulation of phosphatidylcholine biosynthesis by enzyme translocation. Biochim Biophys Acta (1994) 0.96